EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

The new class of drugs-- metalloprotease inhibitors -- in the treatment of heart failure



The new class of drugs-- metalloprotease inhibitors -- in the treatment of heart failure



Klinicheskaia Meditsina 82(5): 7-15




(PDF emailed within 1 workday: $29.90)

Accession: 050679856

Download citation: RISBibTeXText

PMID: 15230033



Related references

Xanthine oxidase inhibitors: an emerging class of drugs for heart failure. European Heart Journal 26(15): 1458-1460, 2005

A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. Journal of Cardiology, 2018

Partial fatty acid oxidation inhibitors: a potentially new class of drugs for heart failure. European Journal of Heart Failure 4(1): 3-6, 2002

Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?. Arthritis and Rheumatism 57(3): 516-523, 2007

Class III drugs and congestive heart failure: Focus on the congestive heart failure-survival trial of antiarrhythmic therapy. American Journal of Cardiology 84(9A): 103R-108R, Nov 4, 1999

Heart failure risk prompts warning labels on diabetes drugs. The concern now is whether this particular class of drugs causes other cardiovascular problems. Harvard Women's Health Watch 14(12): 6-7, 2007

The use of left ventricular assist devices in the treatment of class IV heart failure patients: what the non-heart failure specialist needs to know. Cardiology in Review 21(1): 37-41, 2013

ACE inhibitors vs ARBs: is one class better for heart failure. Cleveland Clinic Journal of Medicine 69(5): 433-438, 2002

Renin inhibitors in chronic heart failure: the Aliskiren Observation of Heart Failure Treatment study in context. Clinical Cardiology 33(9): 536-541, 2011

A new class of drugs for systolic heart failure: The PARADIGM-HF study. Cleveland Clinic Journal of Medicine 82(10): 693-701, 2015

Short-term effects of hypertonic saline solution in acute heart failure and long-term effects of a moderate sodium restriction in patients with compensated heart failure with New York Heart Association class III (Class C) (SMAC-HF Study). American Journal of the Medical Sciences 342(1): 27-37, 2011

ACE inhibitors improve NYHA class in people with chronic heart failure. Evidence-Based Cardiovascular Medicine 10(2): 106-107, 2006

Neutral peptidase inhibitors: New drugs for heart failure. Indian Journal of Pharmacology 35(3): 139-145, June, 2003

ACE inhibitors for 'diastolic' heart failure? reasons not to jump to premature conclusions about the efficacy of ACE inhibitors among older patients with heart failure. European Journal of Heart Failure 3(6): 637-639, 2001

Angiotensin-converting inhibitors in patients with congestive heart failure: a class effect?. American Journal of Cardiology 68(1): 106-108, 1991